Dittus Christopher, Ansell Jack
Department of Medicine, Lenox Hill Hospital, 100 East 77th Street, New York, NY 10075, USA.
Prim Care. 2013 Mar;40(1):109-34. doi: 10.1016/j.pop.2012.11.011. Epub 2012 Dec 27.
Before the advent of oral, targeted anticoagulants, physicians had no choice regarding the type of oral anticoagulant prescribed, as every patient received warfarin. The new oral direct thrombin and factor Xa inhibitors give the prescribing physician, as well as the patient, greater choice. Variation in dosing, half-life, elimination, monitoring, and reversal will help the clinician decide on the appropriate anticoagulant for the appropriate patient. Rather than replace warfarin, each anticoagulant will now have a particular niche, and the decision of which agent to prescribe will be determined at the bedside.
在口服靶向抗凝剂出现之前,医生对于所开口服抗凝剂的类型没有选择余地,因为每个患者都服用华法林。新型口服直接凝血酶抑制剂和Xa因子抑制剂为开处方的医生以及患者提供了更多选择。剂量、半衰期、消除、监测和逆转方面的差异将有助于临床医生为合适的患者选择合适的抗凝剂。现在,每种抗凝剂都将有其特定的适用范围,而不是取代华法林,具体开哪种药将在床边决定。